New cancer drug enters first human safety tests
NCT ID NCT04170153
Summary
This is a first-in-human, early-stage study to find a safe dose and understand how the body processes a new cancer drug called tuvusertib. It is testing the drug alone and in combination with another cancer drug, niraparib, in about 161 people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check for side effects and see how the drug moves through the body, with a secondary look for early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital - Dept of Oncology
Cambridge, United Kingdom
-
Beijing Cancer Hospital
Beijing, China
-
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
-
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona, Spain
-
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
Valencia, Spain
-
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, Spain
-
Mary Crowley Cancer Research Centers
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
National Cancer Center Hospital - Dept of Experimental Therapeutics
Chūōku, Japan
-
National Cancer Center Hospital East - Dept of Experimental Therapeutics
Kashiwa-shi, Japan
-
Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, United Kingdom
-
Royal Marsden Hospital - Dept of Oncology
Sutton, United Kingdom
-
The Christie Hospital - Dept of Oncology
Manchester, United Kingdom
-
The Methodist Hospital Research Institute
Houston, Texas, 77030, United States
-
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.